ID
25293
Beskrivning
Study ID: 101468/166 Clinical Study ID: SKF-101468/166 Study Title: A Phase II, randomised, double-blind, active-controlled, dose-escalation study to determine the maximum well-tolerated starting dose of a new formulation of ropinirole in Parkinson's Disease patients not receiving other dopaminergic therapies Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: Sponsor: GlaxoSmithKline Collaborators: N/A Phase: phase 2 Study Recruitment Status: Completed Generic Name: ropinirole Trade Name: requip Study Indication: Parkinson Disease
Nyckelord
Versioner (2)
- 2017-08-31 2017-08-31 -
- 2017-09-04 2017-09-04 -
Rättsinnehavare
GlaxoSmithKline
Uppladdad den
31 augusti 2017
DOI
För en begäran logga in.
Licens
Creative Commons BY-NC 3.0
Modellkommentarer :
Här kan du kommentera modellen. Med hjälp av pratbubblor i Item-grupperna och Item kan du lägga in specifika kommentarer.
Itemgroup-kommentar för :
Item-kommentar för :
Du måste vara inloggad för att kunna ladda ner formulär. Var vänlig logga in eller registrera dig utan kostnad.
Patient's Daily Diary determination of the maximum well-tolerated starting dose of ropinirole in Parkinson's Disease 101468/166
Patient's Daily Diary determination of the maximum well-tolerated starting dose of ropinirole in Parkinson's Disease 101468/166
Beskrivning
HEALTH RELATED EVENTS
Alias
- UMLS CUI-1
- C1562065
Beskrivning
event
Datatyp
text
Alias
- UMLS CUI [1]
- C0441471
Beskrivning
start date and time
Datatyp
datetime
Alias
- UMLS CUI [1]
- C0808070
- UMLS CUI [2]
- C1301880
Beskrivning
stop date and time
Datatyp
datetime
Alias
- UMLS CUI [1]
- C0806020
- UMLS CUI [2]
- C1522314
Beskrivning
Only tick the box, if the event is still going on.
Datatyp
text
Alias
- UMLS CUI [1]
- C0549178
Similar models
Patient's Daily Diary determination of the maximum well-tolerated starting dose of ropinirole in Parkinson's Disease 101468/166
C0376660 (UMLS CUI [1,2])
C1522634 (UMLS CUI [1,2])
C1301880 (UMLS CUI [2])
C1522314 (UMLS CUI [2])